Skip to main content
. Author manuscript; available in PMC: 2019 Oct 9.
Published in final edited form as: Sci Signal. 2018 Oct 9;11(551):eaat9773. doi: 10.1126/scisignal.aat9773

Fig. 1: Co-existence of ERBB2 amplification and mutations in metastatic breast cancer.

Fig. 1:

(A) Schematic representation of the detection of HER2 mutations in HER2-positive breast cancer patients treated with anti-HER2 therapy for the indicated time. “HER2 3+” refers to tumors that were highly positive for HER2 staining by IHC. (B) OncoPrint software-generated genomic alterations heatmap of the ERBB2-amplified patients available in the MSK database. (C) Graph indicating the proportion of primary or metastatic patients with tumors bearing concomitant mutation and amplification of ERBB2. (D) Kaplen-Meyer curves showing the progression-free survival of the MSK cohort of HER2-positive patients treated with the standard-of-care trastuzumab/pertuzumab/paclitaxel combination (THP). Displayed inset is the hazard ratio (HR) with 95% confidence interval (95%CI) of patients with ERBB2-mutant/amplified (coincident) tumors versus ERBB2-amplified–only tumors.